HEALTH TECHNOLOGY

Endeavour Vision has closed Endeavour Medtech Growth II LP for USD 375 Million to Invest in Transformative Healthcare Technology

Endeavour Vision | April 23, 2021

Endeavour Vision today announced the closure of Endeavour Medtech Growth II (EMG II) LP at a total capital commitment of USD 375 million. The fund will follow the same approach as its predecessor, which was to help early-stage Medtech and digital health advances that advance the quality of care and improve healthcare system efficiencies. EMG II LP was funded by both current and returning investors, including public pension funds, multi-manager funds, family offices, and high-net-worth individuals. EMG II LP expands on Endeavour Vision's two decades of healthcare investment, which has resulted in over USD 500 million invested in 42 businesses, 21 of which have exited through acquisition or IPO.

 

The fund's closure comes as the world prepares for post-pandemic existence after more than a year in the hands of COVID-19, a crisis that has driven the introduction of emerging healthcare technologies, including innovative methods of providing remote patient treatment. Underlying factors such as aging populations, chronic diseases, and tightening healthcare budgets will continue to drive appetite for cost-effective solutions. As a result, healthcare advancement is expected to remain a long-term focus, generating attractive growth and a rich range of opportunities for investors.

 

The fund has now invested more than USD 100 million in seven companies: IntelyCare, CeQur, Rapid Micro Biosystems, SOPHiA GENETICS, Nalu Medical, Lumeon, and Relievant Medsystems.

 

Endeavor Vision is one of the world's leading Medtech and digital health investment teams. The firm collaborates with game-changing businesses, aggressively assisting them with strategic and organizational experience to encourage their global success beyond finance.

 

About Endeavour Vision

Endeavour Vision, established in 2000, is a venture capital and growth equity company that invests in early-stage Medtech and digital health businesses in Europe and the United States. Its foreign investment teams are located in two major healthcare hubs in Geneva, Switzerland, and Minneapolis.

Spotlight

Invest Victoria is the State Government of Victoria's investment attraction agency, fostering long-term economic prosperity by enabling business opportunities and job creation for Victoria.


Other News
MEDICAL DEVICES

Signify Health and Ardent Health Services Collaborate to Improve Healthcare Outcomes

Signify Health, Inc. | December 15, 2022

Signify Health, Inc. a leading healthcare platform that leverages advanced analytics, technology and nationwide healthcare networks to create and power value-based payment programs, today announced an expansion of its relationship with Ardent Health Services, a premier provider of healthcare services with more than 200 sites of care across six states. A former participant in the Center for Medicare and Medicaid Innovation’s Bundled Payments for Care Improvement-Advanced program, Ardent will join a 2023 Signify-enabled accountable care organization (ACO) to implement care transformation, manage risk and provide high-quality, coordinated care for its Medicare patients. Ardent’s affiliated network of facilities and physicians in New Mexico, Oklahoma, Texas, and Kansas will work together with independent providers in a collaborative ACO model to achieve the benefits of scale and to effectively manage risk. The strategic collaboration will support alignment with the Centers for Medicare & Medicaid Services’ (CMS) goal of having all Medicare beneficiaries enrolled in an accountable relationship by 2030. “Ardent is proud of our success to date in value-based care, including the work we have done to transform our patient experience after discharge to achieve an over 26% reduction in our 90-day readmission rate and improve the clinical outcomes among participating patients,” said Marty Bonick, President and CEO of Ardent Health Services. “We are excited to expand our partnership with Signify Health to bring our patients proven preventive and care management services that will help drive better health and improve the overall experience for both patients and care teams.” Earlier this year, Signify Health acquired Caravan Health, a leader in enabling sustainable ACO and population health programs. With this acquisition, Signify Health supports one of the largest networks of at-risk providers and offers one comprehensive platform to manage total cost of care. In 2020 and 2021, 100% of Signify Health’s collaborative ACO participants earned shared savings. According to Tim Gronniger, Chief of Value-based Care Solutions, Signify Health, “CMS has stated that providers will soon be expected to move away from fee-for-service and take accountability for their cost of care. We are thrilled to work with Ardent Health Services to deliver the infrastructure needed to support their success with accountable care. Through our work together, Ardent’s Medicare patients will receive increased access to preventative and in-home services that can help to diminish health inequities and increase savings.” About Signify Health Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to build trusted relationships to make people healthier. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home. For more information on how we are taking health homeward, visit us at signifyhealth.com. About Ardent Health Services Ardent Health Services invests in people, technology and communities. Through its subsidiaries, Ardent owns and operates 30 hospitals and nearly 200 sites of care in six states with more than 24,000 employees, including 1,200+ employed providers. With a focus on evidence-based practices to improve quality care and patient outcomes, 95% of eligible Ardent hospitals received a Leapfrog Hospital Safety Grade of A or B for Fall 2022, compared with 57% of all ranked U.S. hospitals. In 2022, Modern Healthcare recognized six Ardent entities as "Best Places to Work," marking the 14th consecutive year an Ardent facility was recognized. Based in Nashville, Tennessee, Ardent is owned by current and former members of Ardent’s management team; Equity Group Investments (EGI), a Chicago-based private investment firm; and Ventas, Inc. (NYSE: VTR), a publicly traded real estate investment trust.

Read More

FUTURE OF HEALTHCARE, MEDICAL DEVICES

Optimize your time and investment by downloading a networking info app for the 41st Annual JP Morgan Health Care Conference

Novateur Ventures | December 13, 2022

Novateur Ventures, a leading global life sciences advisory firm and Biotechnology Innovation Organization the world's largest advocacy association for biosciences, research and academic institutions, launched an industry networking information app, Event Guide to JPM 2023, which provides listings for an anticipated >200 satellite networking events taking place during the 41st Annual J.P. Morgan Health Care Conference on January 9-12, 2023, in San Francisco, CA. The Event Guide to JPM 2023 app, developed by Novateur Ventures and co-managed by BIO, features event search and filter capabilities, provides links to event and registration information, and in the case of in-person events, loads mapping software for directions to the event. Organizations can also use the app to list their scheduled events being held during the conference timeframe. "It was important for me to develop an app that allowed life science professionals to make important industry connections because, over my career, some of the most transformational relationships I have developed are the direct result of industry networking events. Novateur is delighted to be collaborating with BIO, to give the app a global reach," Ali Ardakani, Founder and Managing Director of Novateur Ventures “I see the app as a natural addition to BIO Partnering at JPM Week. We’re always working to help the industry partner more easily and effectively, and I’m excited to bring the whole JPM Week networking landscape to the palm of your hand. We are excited to be partnering with Novateur on managing and launching this app,” says Mackensie Vernetti, BIO’s Director of Partnering Operations. About Novateur Ventures Novateur Ventures is an established life sciences advisory and investment firm with extensive experience in business development and product development of therapeutics, medical devices, and digital health products. About Biotechnology Innovation Organization BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Good Day BIO is the only daily newsletter at the intersection of biotech, politics and policy. Subscribe here.

Read More

FUTURE OF HEALTHCARE

Skylight Health Announces Series A Preferred Stock Cash Dividend

Skylight Health Group | December 14, 2022

Skylight Health Group Inc. a healthcare platform combining technology and analytics focused on transitioning patients into value based care to drive better health outcomes and experiences in the United States, announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.25% Series A Cumulative Redeemable Perpetual Preferred Shares for the month of January 2023. The Series A Preferred Shares trade under the “SLHGP” stock ticker symbol. In accordance with the terms of the Series A Preferred Shares, the Series A dividend will be payable in cash in the amount of $0.1927 per share on January 20, 2023 to the shareholders of record of the Series A Preferred Stock as of the dividend record date of December 30, 2022. The Company also wishes to update details of the Company’s previously announced shares for debt on September 15 and 16, 2022. The Company will settle a total of $438,400 in debt by issuing an aggregate of 626,286 common shares to the creditors at a deemed price of $0.70 per common share, in satisfaction of the debt. About Skylight Health Group Skylight Health Group is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service model to value-based care (“VBC”) through tools including proprietary technology, data analytics and infrastructure. In an FFS model, payors (commercial and government insurers) reimburse on an encounter-based approach. This puts a focus on the volume of patients per day. In a VBC model, the providers offer care that is aimed at keeping patients healthy and minimizing unnecessary health expenditures that are not proven to maintain the patient’s well-being. This places emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced cost of delivery and drive stronger financial performance from existing practices.

Read More

FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE

BioNJ Hosts Its Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition

BioNJ | December 07, 2022

BioNJ, New Jersey's life sciences trade association, hosted an Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition on Saturday, December 3, at Rutgers Business School. BioNJ's Business Plan Case Competition, which is part of a broader BioNJ strategic initiative of Health Equity in Clinical Trials, was designed to promote the next generation of diverse clinical trial innovators and identify innovative approaches and successful models that can be used nationally to strengthen diversity in clinical trials and expand health equity. BioNJ believes that health equity in clinical trials is critical to deepening the understanding of the safety and efficacy of medicines in under-represented populations, expanding access to medical innovation for these populations and increasing dialogue and trust among the biopharma industry, communities and healthcare systems. By discovering new approaches, utilizing new technologies and developing new business standards to make trials more accessible, we can work to create more agile, efficient and Patient-centered medical research. Eight teams, competing for more than $20,000 in prize money, were tasked with developing a business plan defining a new solution, application or technology to help address this important and challenging problem. Teams identified one particular type of health disparity on which to frame their proposed solutions and connected with community-based organizations to better understand the real-world barriers that exist for their chosen populations to engage in clinical trials. The disease areas on which the respective teams focused included Alzheimer's, heart failure, multiple sclerosis, diabetes type 1 and type 2, colorectal and cervical cancers, and oncology. "There is an urgent need to bring more diversity to clinical trials in order to better serve Patients and their communities…thereby helping to address health inequities. Only by improving diversity in clinical trials will we be able to deepen our understanding of the safety and efficacy of medicines for all populations. I am extremely proud of our teams. Each of the business plans offered a unique out-of-the-box solution – helping advance our ambition to have no Patient left behind." Amadou Diarra, Ph.D., Senior Vice President, Global Policy, Advocacy & Government Affairs for Bristol Myers Squibb; BioNJ Board Member and Chair of the BioNJ Health Equity in Clinical Trials Initiative Live pitch presentations were made throughout the day to a Panel of Judges comprised of industry experts Naikia Atkinson, Director, U.S. Clinical Trials Diversity and Inclusion, Sanofi Schylr Greggs, Director, Technology Operations, Medidata Sharon Hanlon, Head, Clinical Trial Engagement & Enrollment, Bristol Myers Squibb Maribel Hernandez, Vice President, Clinical Operations & Special Projects, PTC Therapeutics Jack Rosenberg, Manager, Investments and Business Development, TrialSpark Del Smith, Co-Founder & CEO, Acclinate Lolita Smith, Program Manager, Rare Disease Diversity Coalition, Black Women's Health Imperative Matt Walz, CEO, TrialBee "Although ultimately three winning teams were presented with cash prizes, each team has made a difference for Patients by offering new solutions and technologies to better serve Patients, build community trust and address gaps in health care delivery," said Paul Howard, Ph.D., BioNJ Business Case Competition Steering Committee Chair and Senior Director, Public Policy for Amicus Therapeutics. "This is just the start as we work to share these proposals more broadly." A white paper with all of the presentations will be published in April and rolled out during BioNJ's acclaimed BioPartnering Conference – which brings together more than 500 industry professionals from around the globe. The three winning teams will present their plans during the April 18 BioPartnering Conference and all of the students are invited to attend to meet the community. About BioNJ BioNJ is the life sciences trade association for New Jersey, representing close to 400 research-based life sciences organizations and stakeholders across the healthcare ecosystem from the largest biopharmaceutical companies to early stage start-ups for nearly 30 years. Because Patients Can't Wait®, BioNJ is dedicated to ensuring a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients Have Access to Lifesaving Medicines.

Read More